Nexium‑Related Esophagitis

Overview

Esophagitis is inflammation of the lining of the esophagus, the muscular tube that carries food from the mouth to the stomach. While many causes exist—acid reflux, infections, medications—this guide focuses on esophagitis that is precipitated or worsened by the proton‑pump inhibitor (PPI) esomeprazole, marketed under the brand name Nexium.

Although PPIs are among the most frequently prescribed drugs in the United States (over 100 million prescriptions in 2022) ¹, a small but clinically relevant subset of patients develop esophageal injury that appears temporally related to Nexium use. The condition is sometimes called “PPI‑induced esophagitis” or “drug‑induced esophagitis.” Reported incidence varies widely—case series suggest 0.1–0.5 % of long‑term users may experience symptoms severe enough to seek medical care². It can affect adults of any age, but risk rises in older adults, patients with swallowing disorders, and those taking high‑dose or extended‑release formulations.

Symptoms

Symptoms of Nexium‑related esophagitis often resemble classic gastroesophageal reflux disease (GERD) but may be more abrupt in onset after initiating or increasing the dose of Nexium. Common manifestations include:

• Odynophagia – painful swallowing, described as a burning or sharp sensation.
• Dysphagia – difficulty or feeling of food sticking in the chest.
• Chest pain – non‑cardiac, retrosternal pain that can mimic heartburn.
• Heartburn – a sour taste or burning behind the breastbone.
• Regurgitation – sensation of acid or food backing up into the throat.
• Sore throat or hoarseness – especially in the morning.
• Cough or wheeze – due to micro‑aspiration.
• Nausea or vomiting – occasionally with blood‑tinged (hematemesis) material.
• Unintended weight loss – from reduced oral intake.
• Fever or chills – rare, may indicate secondary infection.

Because these signs overlap with other esophageal conditions, it is essential to consider medication history when evaluating new or worsening symptoms.

Causes and Risk Factors

How Nexium Can Trigger Esophagitis

Nexium reduces gastric acid by irreversibly blocking the H⁺/K⁺‑ATPase pump in parietal cells. While this effect is therapeutic for ulcer disease and GERD, several mechanisms can paradoxically damage the esophagus:

• Retention of the tablet in the esophagus – Large or enteric‑coated tablets can adhere to the mucosa if not swallowed properly, causing localized chemical irritation.
• Altered esophageal motility – PPIs may affect lower esophageal sphincter tone and peristalsis, leading to prolonged exposure of the esophageal lining to the drug.
• Changes in microbiome – By suppressing acid, PPIs allow overgrowth of bacteria and fungi that can colonize the esophagus, especially in immunocompromised patients.
• Hypersensitivity reactions – Rare immune‑mediated responses to the drug’s excipients (e.g., magnesium stearate) can cause inflammation.

Who Is Most at Risk?

• Adults > 60 years old (reduced esophageal clearance).
• Patients with pre‑existing motility disorders (achalasia, diffuse esophageal spasm).
• Individuals with structural abnormalities (strictures, Schatzki rings, hiatal hernia).
• People who take the medication with insufficient water or lie down immediately after swallowing.
• Those on high‑dose (≥40 mg daily) or extended‑release formulations.
• Patients with concomitant use of other esophagitis‑causing drugs (e.g., doxycycline, bisphosphonates, potassium chloride).
• Immunocompromised patients (cancer chemotherapy, HIV) who are prone to opportunistic esophageal infections.

Diagnosis

Diagnosing Nexium‑related esophagitis requires a combination of clinical history, physical examination, and targeted investigations to rule out other causes.

Step‑by‑Step Diagnostic Approach

1. Medication review – Confirm timing, dose, and formulation of Nexium; assess adherence to proper swallowing technique.
2. Symptom questionnaire – Use validated tools such as the Dysphagia Symptom Questionnaire (DSQ) to quantify severity.
3. Physical examination – Look for signs of malnutrition, cervical lymphadenopathy, or oral candidiasis.
4. Upper endoscopy (esophagogastroduodenoscopy, EGD) – Gold standard. Findings may include:
   • Erythema, edema, or ulcerations localized to the mid‑ or distal esophagus.
   • White plaques suggestive of Candida overgrowth.
   • Biopsy to exclude eosinophilic esophagitis, infection, or malignancy.
5. Barium swallow (esophagram) – Helpful if dysphagia is prominent, to detect strictures or motility disorders.
6. pH‑impedance monitoring – Differentiates acid‑mediated injury from non‑acidic drug‑related inflammation.
7. Laboratory tests – CBC (look for anemia), inflammatory markers, and, if infection is suspected, fungal cultures.

Treatment Options

Management focuses on removing the offending agent, promoting mucosal healing, and addressing any underlying contributors.

1. Discontinue or Adjust Nexium

• Short‑term cessation – Stop Nexium for 2–4 weeks while monitoring symptoms.
• Switch to an alternative PPI (e.g., omeprazole) or an H₂‑blocker (ranitidine, famotidine) if acid suppression remains necessary.
• For patients who must stay on a PPI, lower the dose or use a tablet‑splitting** technique** (if appropriate) to reduce esophageal contact time.